• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

激素受体的表达预测高级别浆液性卵巢癌的生存和铂类敏感性。

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China.

Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China.

出版信息

Biosci Rep. 2021 May 28;41(5). doi: 10.1042/BSR20210478.

DOI:10.1042/BSR20210478
PMID:33891016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8112847/
Abstract

High-grade serous ovarian cancer (HGSOC) has abundant expression of hormone receptors, including androgen receptor (AR), estrogen receptor α (ER), and progesterone receptor (PR). The effects of hormone receptors on prognosis of HGSOC were first evaluated in online databases. Their prognostic values were then explored and validated in our inhouse TJ-cohort (92 HGSOC patients) and in a validation cohort (33 HGSOC patients), wherein hormone receptors were detected immunohistochemically. High expression of hormone receptors denoted longer progression-free survival (PFS), overall survival (OS), and platinum-free interval (PFI). Platinum-sensitive patients had higher expression of hormone receptors than their counterparts. Correlation analysis revealed significant positive correlations between hormone receptors expression and survival. AR, ER, and PR had predictive and prognostic values, alone and in combination. By receiver operating characteristic curve (ROC) analysis, co-expression of AR, ER, and PR had an improved predictive performance with an area under the curve (AUC) value of 0.945. Expression of hormone receptors predicts survival and platinum sensitivity of HGSOC. AR, ER, and PR might be feasible prognostic biomarkers for HGSOC by immunohistochemical analysis.

摘要

高级别浆液性卵巢癌 (HGSOC) 大量表达激素受体，包括雄激素受体 (AR)、雌激素受体 α (ER) 和孕激素受体 (PR)。首先在在线数据库中评估了激素受体对 HGSOC 预后的影响。然后在我们的内部 TJ 队列 (92 例 HGSOC 患者) 和验证队列 (33 例 HGSOC 患者) 中进行了探索和验证，其中通过免疫组织化学检测了激素受体。激素受体的高表达表示无进展生存期 (PFS)、总生存期 (OS) 和铂无间隔期 (PFI) 更长。铂敏感患者的激素受体表达高于其对应患者。相关性分析显示，激素受体表达与生存之间存在显著的正相关。AR、ER 和 PR 单独或联合具有预测和预后价值。通过接收者操作特征曲线 (ROC) 分析，AR、ER 和 PR 的共表达具有改善的预测性能，曲线下面积 (AUC) 值为 0.945。激素受体的表达可预测 HGSOC 的生存和铂敏感性。通过免疫组织化学分析，AR、ER 和 PR 可能是 HGSOC 可行的预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/49943b2c4cef/bsr-41-bsr20210478-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/cd02946a8872/bsr-41-bsr20210478-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/02437f8d1db7/bsr-41-bsr20210478-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/2b05d28a7da3/bsr-41-bsr20210478-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/2e12d29ac038/bsr-41-bsr20210478-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/9a8f0308b6a8/bsr-41-bsr20210478-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/49943b2c4cef/bsr-41-bsr20210478-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/cd02946a8872/bsr-41-bsr20210478-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/02437f8d1db7/bsr-41-bsr20210478-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/2b05d28a7da3/bsr-41-bsr20210478-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/2e12d29ac038/bsr-41-bsr20210478-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/9a8f0308b6a8/bsr-41-bsr20210478-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8396/8112847/49943b2c4cef/bsr-41-bsr20210478-g6.jpg

相似文献

1
Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.激素受体的表达预测高级别浆液性卵巢癌的生存和铂类敏感性。
Biosci Rep. 2021 May 28;41(5). doi: 10.1042/BSR20210478.
2
Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.生物信息学分析确定了一种卵巢癌铂耐药相关风险特征。
Cancer Med. 2020 Feb;9(3):1242-1253. doi: 10.1002/cam4.2692. Epub 2019 Dec 19.
3
A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression.基于激素受体表达的临床适用的高级别浆液性卵巢癌分子分类。
Sci Rep. 2016 May 3;6:25408. doi: 10.1038/srep25408.
4
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.Ki-67 水平和激素受体表达在低级别浆液性卵巢癌中的预后意义：肿瘤银行卵巢癌网络的研究。
Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11.
5
Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment.激素受体在原发性和复发性高级别浆液性卵巢癌中的表达及其在早期维持治疗中的意义。
Int J Mol Sci. 2022 Nov 17;23(22):14242. doi: 10.3390/ijms232214242.
6
Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers.原发性和复发性高级别浆液性卵巢癌之间的激素受体表达谱存在差异。
Oncotarget. 2017 May 16;8(20):32848-32855. doi: 10.18632/oncotarget.15858.
7
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.雌激素受体和孕激素受体肿瘤表达在丹麦卵巢癌患者中的预后价值：来自“MALOVA”卵巢癌研究
Oncol Rep. 2007 Nov;18(5):1051-9.
8
Androgen receptor status predicts development of brain metastases in ovarian cancers.雄激素受体状态可预测卵巢癌脑转移的发生。
Oncotarget. 2017 Jun 20;8(25):41143-41153. doi: 10.18632/oncotarget.17068.
9
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.在卵巢癌中 PTEN 表达的临床和病理相关性：来自卵巢肿瘤组织分析联盟的多中心研究。
Br J Cancer. 2020 Sep;123(5):793-802. doi: 10.1038/s41416-020-0900-0. Epub 2020 Jun 18.
10
Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.干扰素调节因子 1 是高级别浆液性卵巢癌铂耐药和生存的独立预测因子。
Gynecol Oncol. 2014 Sep;134(3):591-8. doi: 10.1016/j.ygyno.2014.06.025. Epub 2014 Jul 1.

引用本文的文献

1
Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.新型蛋白预后标志物与卵巢癌免疫治疗疗效相关。
J Ovarian Res. 2024 Sep 28;17(1):190. doi: 10.1186/s13048-024-01518-w.
2
Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options.激素受体与上皮性卵巢癌：生物学及治疗选择的最新进展
Biomedicines. 2023 Aug 1;11(8):2157. doi: 10.3390/biomedicines11082157.
3
Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer.

本文引用的文献

1
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.miR-509-3 通过调节同源重组修复增强 PDX 模型中卵巢浆液性癌对 PARPi 的合成致死作用。
J Hematol Oncol. 2020 Jan 31;13(1):9. doi: 10.1186/s13045-020-0844-0.
2
Long Non-Coding RNA LINC00511 Mediates the Effects of ESR1 on Proliferation and Invasion of Ovarian Cancer Through miR-424-5p and miR-370-5p.长链非编码RNA LINC00511通过miR-424-5p和miR-370-5p介导ESR1对卵巢癌增殖和侵袭的影响。
Cancer Manag Res. 2019 Dec 27;11:10807-10819. doi: 10.2147/CMAR.S232140. eCollection 2019.
3
A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
β-抑制蛋白与糖皮质激素受体联合在上皮性卵巢癌中的预后价值
Front Oncol. 2023 Mar 10;13:1104521. doi: 10.3389/fonc.2023.1104521. eCollection 2023.
4
Molecular Management of High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌的分子管理
Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777.
5
What's beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.高级别浆液性卵巢癌中BRCA突变状态之外还有什么？激素受体表达在一个大型BRCA基因分型的卵巢癌患者队列中的影响：一项回顾性队列研究。
Cancers (Basel). 2022 Sep 22;14(19):4588. doi: 10.3390/cancers14194588.
6
Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors.孕激素受体免疫组化的诊断和预后影响：一项评估超过 16000 个肿瘤的研究。
Anal Cell Pathol (Amst). 2022 Aug 8;2022:6412148. doi: 10.1155/2022/6412148. eCollection 2022.
7
Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis.不同高级别浆液性卵巢癌亚型的模型细胞系和组织在局部雌激素生物合成方面存在差异。
Cancers (Basel). 2022 May 24;14(11):2583. doi: 10.3390/cancers14112583.
活性氧物种评分系统预测卵巢癌患者对顺铂的敏感性和预后。
BMC Cancer. 2019 Nov 8;19(1):1061. doi: 10.1186/s12885-019-6288-7.
4
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.组蛋白甲基转移酶DOT1L是卵巢癌细胞中雌激素受体α信号传导的功能性组成部分。
Cancers (Basel). 2019 Nov 4;11(11):1720. doi: 10.3390/cancers11111720.
5
Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions.卵巢高级别浆液性癌的自然史：来自于排卵抑制和 p53 缺陷病变中孕激素清除的时间效应。
Mod Pathol. 2020 Jan;33(1):29-37. doi: 10.1038/s41379-019-0370-1. Epub 2019 Sep 26.
6
Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.激素受体表达模式定义了具有临床意义的子宫内膜样卵巢癌亚群。
Gynecol Oncol. 2019 Nov;155(2):318-323. doi: 10.1016/j.ygyno.2019.09.001. Epub 2019 Sep 5.
7
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.PARAGON（ANZGOG-0903）：一项在雌激素和孕激素受体阳性、无症状、CA125 进展的复发性卵巢癌患者中应用阿那曲唑的 2 期研究。
J Gynecol Oncol. 2019 Sep;30(5):e86. doi: 10.3802/jgo.2019.30.e86.
8
Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome.卵巢癌中的非经典雌激素信号传导可提高化疗敏感性并改善患者预后。
Theranostics. 2019 May 31;9(13):3952-3965. doi: 10.7150/thno.30814. eCollection 2019.
9
BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.BRCA1 减弱孕激素对正常人类乳腺上皮细胞增殖和 NFκB 激活的作用。
J Mammary Gland Biol Neoplasia. 2019 Sep;24(3):257-270. doi: 10.1007/s10911-019-09431-5. Epub 2019 May 18.
10
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.上皮性卵巢癌：精准医学时代的治疗进展。
CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17.